Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
Send Cancel

Human anti-cancer drugs could help Tasmanian devils
Tasmanian devils are considered endangered as a result of devil facial tumour 1.
RTKs have ‘an important role’ in sustaining transmissible cancers

Key drugs used to treat cancer in humans may also be useful in the fight against transmissible cancers in Tasmanian devils.

This is according to a new study by the University of Cambridge, which found that certain drugs used in humans were able to efficiently stop the growth of devil cancer cells in the lab.

The research, published in the journal Cancer Cell, shows that molecules known as receptor tyrosine kinases (RTKs) have an important role to play in sustaining the growth and survival of transmissible cancers in devils. Drugs targeting RTKs have already been developed for human cancers.

Tasmanian devils are considered endangered as a result of devil facial tumour 1 (DFT1), which is passed between animals through biting and causes disfiguring facial tumours. Usually fatal, DFT1 has spread throughout Tasmania since it was first seen in 1996, causing significant declines in devil populations.

Routine diagnostic screening in 2014 uncovered a second transmissible cancer in the species. With the naked eye, facial tumours caused by devil facial tumour 2 (DFT2) cannot be distinguished from those caused by DFT1, but analysis has shown they differ at a biological level.

Cambridge researchers found striking similarities between the two cancer types; in terms of genetics, tissues of origin, the way in which the cancer cells mutate and possible drug targets.

First author Dr Elizabeth Murchison said: “The story of Tasmanian devils in recent years has been a very concerning one. This study gives us optimism that anti-cancer drugs that are already in use in humans may offer a chance to assist with conservation efforts for this iconic animal.”

Become a member or log in to add this story to your CPD history

Nominations for 2019 RSPCA Honours Awards now open

News Story 1
 People across the UK are being urged to nominate a standout animal champion for the 2019 RSPCA Honours Awards.

The awards recognise those who have worked tirelessly to improve animal welfare, campaigned on behalf of animals, or shown true bravery. Previous winners include comedian John Bishop, who was awarded Celebrity Animal Champion of the Year, and 11-year-old Lobby Cantwell, who raised more than £1,000 for the charity through mountain climbs and bike rides.

To submit a nomination or find out more about the awards visit the RSPCA website. Nominations will remain open until 4 pm on Friday, March 15.  

Click here for more...
News Shorts
New £1m project to investigate dairy cow lameness

Scotland’s Rural College (SRUC) is leading a new £1 million research project to investigate the causes of lameness in dairy cows.

One in three dairy cows are affected by lameness every day in the UK, costing the industry an estimated £250 milion annually.

The project will take three years to complete and is due to finish by November 2021.

Professor Georgios Banos of SRUC commented: “In addition to pain and discomfort to the animal, lameness is associated with decreased milk production and inflated farm costs.

“Among cows raised in the same environment, some become lame while others do not. Understanding the reasons behind this will help us develop targeted preventive practices contributing to enhanced animal welfare and farm profitability.”